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We evaluated adhesive molecule ligand presentation on targeted particles in a model of 
mesentery inflammation. Our intravital microscopy results demonstrate the optimal particle 
design is heavily dependent on the surface expression of the endothelial cells, producing better 
adhesion with more particle ligand for the lesser-expressed receptor. 
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Vascular-targeted carriers (VTCs) are designed as leukocyte mimics, decorated with 
ligands that target leukocyte adhesion molecules (LAMs) and facilitate adhesion to diseased 
endothelium. VTCs require different design considerations than other targeted particle therapies; 
adhesion of VTCs in regions with dynamic blood flow requires multiple ligand-receptor (LR) 
pairs that provide particle adhesion and disease specificity. Despite the ultimate goal of 
leukocyte mimicry, the specificity of multiple LAM-targeted VTCs remains poorly understood, 
especially in physiological environments. Here, we investigate particle binding to an inflamed 
mesentery via intravital microscopy using a series of particles with well-controlled ligand 
properties. We find that the total number of sites of a single ligand can drive particle adhesion to 
the endothelium, however, combining ligands that target multiple LR pairs provides a more 
effective approach. Combining sites of sialyl Lewis A (sLe
A
) and anti-intercellular adhesion 
molecule-1 (aICAM), two adhesive molecules, resulted in ~3-7-fold increase of adherent 
particles at the endothelium over single-ligand particles. At a constant total ligand density, a 
particle with a ratio of 75% sLe
A
: 25% aICAM resulted in more than 3-fold increase over all 
over other ligand ratios tested in our in vivo model. Combined with in vitro and in silico data, we 
find the best dual-ligand design of a particle is heavily dependent on the surface expression of 
the endothelial cells, producing better adhesion with more particle ligand for the lesser-expressed 
receptor. These results establish the importance of considering LR-kinetics in intelligent VTC 
ligand design for future therapeutics.  
 
Keywords: vascular-targeted carrier, dual-targeted particle, ligand-receptor pair, 
leukomimietics, intravital microscopy, particle adhesion  
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Particulate drug delivery was initially developed to package systemically toxic drugs into 
inert particle carriers, thereby selectively releasing active cargo to a diseased target. This 
approach should dramatically increase treatment efficacy by delivering more drug into the 
diseased tissue while eliminating systemic release, thereby mitigating toxic side effects. While 
this concept has not yielded a true “magic bullet” to date, packaging small molecule drugs into 
particles dramatically alters their pharmacokinetic/dynamic behavior and provides opportunities 
to direct drugs into diseased targets depending on their size, shape, and composition.
1–4
 Many 
diseases manifest in the upregulation or overexpression of certain cellular surface receptors; 
therefore, tissue specificity can be enhanced with use of ligand-receptor (LR) pairs. Particulate 
drug carriers can be coated with ligands complimentary to these receptors, providing a lock and 
key approach to disease-specific delivery. In principle, the concept of LR pairs seems 
straightforward, however, implementation of actively targeted particles has proved challenging.
5
 
Nanoparticle therapeutics with applications in cancer have driven research in the field. Despite 
conflicting results in overall success,
5–7
 a handful of candidates are currently in the clinical trial 
pipeline for cancer applications.
6,8
 
Vascular-targeted carriers (VTCs) are an emerging area of research within particulate 
drug delivery. We define VTCs as particles designed with surface adhesive ligands that mimic 
those of leukocytes. During inflammation, activated endothelial cells (ECs) upregulate surface 
leukocyte adhesion molecules (LAMs), including selectins, intercellular adhesion molecule-1 
(ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1).
9
 Importantly, ECs shed their 
glycocalyx barrier, enabling leukocytes to interact directly with the EC surface.
10
 Surface ligands 
on circulating leukocytes facilitate rolling on and firm capture to activated ECs, and assist in 
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extravasation into tissue to perform various immune functions.
11
 This leukocyte adhesion 
cascade (LAC) is an important mechanism for normal immune function, but is also indicative of 
excessive cell recruitment that occurs early in many diseases.
9,11
 Overexpression of LAMs 
represent potential targets for the design of particulate therapeutics; VTCs have been designed 








Success of VTCs relies heavily on LR interactions with overexpressed LAMs on diseased 
ECs. VTCs are unique in that they must adhere to diseased ECs under rapid blood flow 
conditions, unlike other particles targeted to tissue spaces. Once localized to the endothelium, the 
interactions between LR pairs dictate adhesion and ultimate drug carrier efficacy. VTC and EC 
surface bonds must form rapidly to overcome particle momentum in flow. Capture and firm 
arrest at the surface will depend on the kinetics of the LR engaged pair and the aggregate 
strength of those interactions. Particle ligand total receptor avidity and specificity must be 
balanced; excessive avidity can lead to off target binding and immune responses due to rapid 
opsonization of non-native proteins, while insufficient LR avidity can result in minimal 
binding.
18
 The design of VTC ligands must correspond with receptors in the targeted disease 
state; a ligand for the immediate onset of disease may not function efficiently in a chronic 
response.
19,20
 Given the fluctuation of receptors on ECs and the presence of blood flow, 
leukocytes achieve adhesion with multiple LR pairs, where each LR pair provides a unique 
benefit of capture, firm adhesion or transmigration, based on spatiotemporal expression on the 
diseased ECs. Notably, selectin receptors facilitate leukocyte capture and rolling, yet 
physiological levels of this LR pair are not enough to achieve firm adhesion on inflamed ECs. 
Firm adhesion requires secondary LR pairs, usually involving cell adhesion molecules (CAMs), 
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which are expressed at a lower EC surface density with more favorable kinetics for firm 
adhesion.
9,11
 Through the synergistic effects of these two LR pairs, leukocytes efficiently 
respond to inflammation on diseased tissues in vivo.  
Despite the goal of LAC mimicry, the use of multiple LAM ligands on VTCs remains 
poorly understood. Most studies of VTCs have focused on particle designs with a single LR pair, 
with emphasis on the final disease outcome due to the delivered drug. Efficacy studies that have 
probed dual ligands are largely qualitative, comparing multi-ligand particles to the single ligand 
counterparts with minimal control over the total particle ligand presentation.
5,18,21–23
 Additional 
studies have probed the importance of ligand ratios between two LR pairs in static conditions, 
which fail to capture LR pair dynamics under physiologically relevant flows.
21,24
 To study LR 
kinetics under flow, multiple research groups have used protein-coated plates to study the 
adhesion an  rolling of dual-targeted particles in vitro.
25–30
 However, these studies lack the 
complexity of a true diseased endothelium, as spatiotemporal LAM expression varies widely.
31
  
To address these gaps in understanding, we have designed 500 nm polystyrene spheres 
with controlled ligand densities and evaluated particle adhesion in physiological environments. 
Polystyrene particles serve as model VTCs in this work as it enables evaluation of ligand surface 
properties on a monodisperse particle population; we anticipate the particle dynamics observed 
here will be applicable to translatable particle formulations, such as poly(lactic-co-glycolic acid) 
(PLGA). While the 500 nm size is just outside the 100 – 200 nm range typically considered for 
drug delivery, 500 nm spheres offer easier surface modification, characterization and imaging, 
and have previously been shown to have similar blood flow adhesion dynamics as the 100-200 
nm spheres.
32,33
 We investigated both single and dual LR pairs, exploiting selectin and 
intercellular adhesion molecule-1 (ICAM-1) mediated paths of adhesion by designing particles 
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with sialyl Lews A (sLe
A
) and anti-ICAM-1 (aICAM-1). The synergy between selectin:sLe
A
 (via 
PSGL-1) and ICAM-1:β2-integrin LR pairs drives optimal leukocyte adhesion during 
inflammatory events in vivo
9
; thus, representing a synergistic, leukocyte mimetic VTC system. 
Furthermore, the drastically different rates of interaction between the carbohydrate-selectin LR 
pair and antibody-CAM LR pair offers the opportunity for evaluating the role of LR pair kinetics 
in VTC design.
34,35
 Notably, we evaluated these particles in a model of inflamed mesentery using 
intravital microscopy to capture a dynamic in vivo environment. Our results show that 





 dictates particle adhesion in vitro and in vivo 
We utilized a parallel plate flow chamber (PPFC) assay to investigate the role of sLe
A 
density on particle adhesion under physiological blood flow conditions. A series of four particle 
types (A-D) was prepared with increasing sLe
A 
surface density (Figure 1A). SLe
A
 site densities 
were quantified by flow cytometry (Table 1), with representative gating shown in Figure S1 and 
reaction conditions in Figure S2. Human umbilical vein endothelial cell (HUVEC) monolayers 
were prepared and activated with TNF-α for 4 hrs prior to experiments. Representative 
fluorescent images of particle binding in the PPFC assay are shown in Figure 1B. Minimal non-
specific particle binding was observed for particles functionalized with an IgG-isotype control of 
varied densities, as shown in Figure S3. Particle adhesion from sLe
A
 targeted particles was 
determined and non-specific binding from control particles at corresponding site densities were 
subtracted out to quantify target-specific adhesion (Figure 1C). Increasing the sLe
A
 density on 
500 nm particles from 5,000 sites/µm
2
 to 40,000 sites/µm
2 
resulted in increased particle 
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adhesion. We observed a 2-fold increase in particle binding from A to B; additional sLe
A
 on C 
and D resulted in further increased adhesion (3- and 6-fold increases over A, respectively).  
 We were interested if the increase in sLe
A
 site density could produce a similar increase in 
particle binding in vivo, which we observed with real-time intravital fluorescence microscopy. 
Fluorescent particle types A-D were visualized at the surface of the inflamed blood vessel in 
vivo, with qualitative differences in particle adhesion shown in representative still images of 
Figure 2A. The vessel walls of selected veins are indicated with black arrows; particles found in 
other vessels, including adjacent capillaries, were not included in the adhesion analysis. Particle 
adhesion and rolling densities were determined (Figure 2B) and the rolling velocities of 
corresponding particles are shown (Figure 2C). No particle binding or adhesion was observed for 
control particles with isotype-control IgG (Video S1). Movies of particles B & C rolling in vivo 
can be seen in Videos S2 and S3. 
 Particles A-D successfully adhered to the inflamed endothelium via both rolling and firm 
arrest. Particle A exhibited the fastest rolling velocity, which corresponded to the lowest 
occurrence of particles firmly arrested or rolling at the wall. Particle B exhibited a decreased 
rolling velocity compared to particle A (p<0.0001), which corresponded to an increased presence 
of particles at the wall. Particles C and D had similar low rolling velocities (p=0.2), which 
resulted in more firmly bound particles; Particle C was the most effective, with a ~30-fold 
increase of total adherent particles over A (p=0.014). This corresponded to a ~30-fold increase in 
rolling particles and a ~20-fold increase in firmly arrested particles (p=0.012 and p=0.042, 
respectively). Additionally, particle C produced a ~9-fold increase in total adherent particles over 
B (p=0.019), with a 7.5-fold increase in number of rolling particles and a ~10-fold increase in 
firmly arrested particles (p=0.019 and p=0.051 respectively). We observed no statistical 
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difference between particles C and D for either rolling or firmly arrested particles, however the 
average number of adherent particles was less for particle D (p>0.05 for all interactions). As the 
average velocity of rolling particles decreased, more particles of that type firmly adhered to the 
inflamed vessel. Particle types C and D had the highest sLe
A 
surface densities and yielded the 
highest amount of firmly arrested and rolling particles. This suggests a sLe
A
 saturation point in 
vivo. 
Use of dual-targeting ligands enhances particle binding in vivo 
We next explored how a mix of targeting ligands could further improve VTC adhesion in 
vivo. We compared a series of particles with varied sLe
A
 and anti-ICAM (aICAM) ligand 
densities, as shown in Figure 3, to determine if particle adhesion from a dual-targeted particle is 
merely the sum from the two individual ligands. The adhesion and rolling propensity of these 
particles were evaluated in the in vivo model of acute mesentery inflammation, as before.  




 or aICAM, 
respectively, while particle F was the direct sum of the two ligands, for a total site density of 
10,000 sites/µm
2
 (Table 1). At a constant ligand density of 5,000 sites/µm
2
, varying the ligand 
type from sLe
A
 (A) to aICAM (E) resulted in a statistically insignificant increase in particles 
rolling or firmly arrested on the vessel wall (p=0.5). However, combining sites of sLe
A
 and 
aICAM on the same particle (F) resulted in a significant increase of adherent particles at the wall 
(~7-fold increase over A, p=0.005, and ~3-fold increase over E, p=0.012). For particle F, the 
number of firmly arrested particles was a ~5-fold (p=0.034) and ~3-fold (p=0.049) increase over 
A and E, respectively. No differences were observed in the number of rolling particles between 
groups, however, there were differences in rolling velocities. Particle A had the fastest rolling 
velocity, while particle F had the slowest rolling velocity, corresponding to the most effective 
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adhesion at the wall. A video of particle type F adhering in vivo can be found in Video S4. With 
particle types A, E, and F, a decrease in observed particle rolling velocity corresponded to more 
particle adhesion at the vessel wall in vivo.  
To probe the effect of total site density, we investigated particles B, G, and H, which each 
had twice the site densities of particles A, E, and F, respectively (Figure 3B). At these higher 
total site densities, varying the ligand from sLe
A
 (B) to aICAM (G) produced a minimal increase 
of particle presence at the wall, in either firmly arrested or rolling numbers, neither of which 
were significant from observation for particles A and E. Again, combining sites of sLe
A
 and 
aICAM on the same particle (H) resulted in a significant increase of adherent particles at the wall 
(~2-fold increase over B, p=0.039, and ~3-fold increase over G, p=0.030). The number of firmly 
arrested particles of type H resulted in a ~4.3-fold (p=0.007) and ~3-fold (p= 0.011) increase 
over E and G, respectively. The relationship between rolling velocity and total particle adhesion 
was not linear in Figure 3B, owing to the fact that no particles were detected rolling for particle 
type G. Interestingly, increasing the total site density of dual-targeted particles from 10,000 (F) 
to 20,000 (H) sites/µm
2 
did not provide a significant increase in adhesion (p=0.5).  
Particle adhesion of both dual-targeted particle types (F, H) indicate a more than additive 
effect of each individual-targeting ligand. We further compared the benefit of dual-targeting 
ligands on a single particle by keeping the total number of sites constant in order to eliminate any 
possible enhancement due to the change in total density (as studied in Figure 3). We developed a 
series of five particles with a constant total of 10,000 sites/µm
2
, given the lack of benefit when 
increasing to 20,000 sites/µm
2
 (F, H). We varied ratios of sLe
A
 and aICAM (Figure 4A and 
Table 1) and tested these in the model of acute mesentery inflammation. Figure 4B is a 
representative image of the highest dual-targeted fluorescent particle binding in vivo. 
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Representative movies of particle types F, I, and J can be found in Videos S4-6, respectively. For 
all five particle types, the number density of both rolling and firmly arrested particles are 
quantified in Figure 4C. The ligand combination on particle I resulted in a significantly increased 
number of firmly arrested particles compared to all other combinations (p<0.001 for all 
comparisons), with at least a ~3-fold increase over all other ligand combinations. Similar 
numbers of rolling particles were observed with all five conditions; however as shown in Figure 
4D, slight decreases in rolling velocities were observed for particles I and F compared to B and J. 
 
Optimal dual ligand ratio on particle varies with EC surface expression 
 Given the dramatic increase in adhesion of particle I in vivo over all other ligand 
combinations in the particle series (Figure 4A), we investigated the dependence of particle 
adhesion on the corresponding surface expression of LAMs on the endothelium. As shown in in 
Figures 5A and S4, TNF-α activation of HUVECs resulted in elevated levels of both ICAM and 
E-selectin surface expression, albeit maximally at different times. Basal levels of ICAM were 
observed in all three conditions, while no basal E-selectin was observed. We further quantified 
these changes in expression level over time using flow cytometry (representative gating in Figure 
S5), with fold changes over unactivated cells shown in Figure 5B. Maximum E-selectin was 
observed between 4 and 8 hrs, while maximum ICAM expression was observed at 24 hrs. With 
maximum E-selectin expression, there was elevated ICAM expression, with the inverse true for 
E-selectin at time points of maximum ICAM expression. We explored particle adhesion of the 
panel of five particle types from Figure 4A in a PPFC with activated HUVECs at 4 hrs (Figure 
5C) and 24 hrs (Figure 5D) to probe the importance of HUVEC surface expression on particle 
adhesion. At 4 hrs, particle J resulted in superior particle adhesion, corresponding to ~1.5-fold 
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more bound particles than all other particle types (p<0.05 between J and particles I, F, and G). At 
24 hrs, particle I resulted in maximal particle adhesion, with ~6-fold more bound particles over 
all other particle types (p<0.0001 between all particle types).  
To further explore these LR-pair interactions, we developed a computational model of 
binding at an endothelial surface, taking into account the number of ligands on the particle (NL-
aICAM, NL-sLe
A
), the number of receptors on the endothelium (NR-ICAM, NR-selectin) and the 
dynamic properties of the particles under laminar flow. These variables were captured in the 
particle attachment (ka) and detachment (kd) rates at the boundary. The geometry of the two-
dimensional channel is shown in Figure 6A, which has a reactive region along the bottom of the 
surface; an example concentration profile within the fluid following the simulation is also shown. 
Adherent particles at the reactive surface are not visualized within the channel concentration 
profiles an  are computed independently. Furthermore, only firmly bound particles are 
quantified at the surface; particle rolling was not incorporated in the model. From our derived 
expressions, we found that ka and kd depend dramatically on shear rate at constant ligand and 
receptor densities (Figure S6A). The ka decreases slightly with increasing shear rate, while kd 
increases over five orders of magnitude between tested shear rates of 10 and 1000 s
-1
. The 
dependency of ka and kd on shear rate translates to differences in particle adhesion at the surface, 
as shown in Figure S6A.  
Using this model, we probed the differences in particle adhesion based on particle ligand 
ratios, for various surface receptor presentations of ICAM and selectin. To confirm that our 
model was sensitive to ligand and receptor densities of both LAM pairs, we independently varied 
NL and NR for both sLe
A
/selectin and aICAM/ICAM at a constant shear rate of 200 s
-1 
(average 
channel velocity 1.67 mm/s). Figure 6B shows the change in rate of bound particles (B) as a 
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result of increasing NL-sLe
A
, all else constant. This corresponds with results in Figure 1, 
confirming that the rate of B increases with increasing NL-sLe
A
 density, but with diminishing 
returns. Similarly, Figure 6C shows as NR-selectin increases, all else constant, the rate of B 
increases. These trends held true for aICAM/ICAM pairing as well (data not shown).  
Having shown that our model could accurately capture the binding dynamics at the 
reactive surface for both LAMs, we compared the binding efficiencies of the particle series 
shown in Figure 4A over a range of NR combinations. The heat maps in Figure 6D show the total 
number B after 1 second for increasing NR-selectin (x-axis) and NR-ICAM (y-axis) expression, 
with blue and red indicating conditions of more and fewer adherent particles, respectively. 
Immediately, we observe distinct combinations of optimal binding for each particle type. Particle 
B, 100% sLe
A
, yields conditions with the largest magnitude of binding for the range of conditions 
modeled, yet also yields negligible binding for over half of the conditions tested. Increasing the 
amount of aICAM on the particles while reducing the amount of sLe
A
 slowly shifts the 
conditions of favorable binding towards ICAM expression. Each of these five particle 
combinations with varied NL
 
yield unique binding profiles as a function of LAM surface 
expression (heat map differences between particles shown in Figure S6B). Figure 6 highlights 
the complex interplay between ligand and receptor densities combined with receptor-ligand 
kinetics. For each particle type, endothelial surface expression prescribes its overall binding 
abilities. Thus, when designing targeted VTCs, it is key to understand endothelial surface 
expression patterns.  
 
DISCUSSION 
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 Despite studies successfully employing dual-targeted particles for vascular delivery, gaps 
still remain in understanding the effect of varied particle ligand densities and ratios. Here, we 
report a distinct interplay between endothelial receptor expression and particle ligand patterning 
that determines particle adhesion. To our knowledge, this is the first report of intravital 
microscopy investigations of dual-targeting VTCs in vivo, thus allowing evaluation of both 
particle rolling and firm adhesion. We find that increasing the number of sites of sLe
A
 on 
particles increases adhesion in vitro and in vivo. We also find that the dual-targeting particle 
designs result in adhesion superior to that of the linear addition of each individual ligand, 
indicating a multifaceted relationship in LR interactions. Overall, a 50%-50% split in ligand 
coverage, which is often studied, did not result in the best adhesion tendencies in vitro or in vivo 
under the conditions explored; rather, intermediate ligand regimes produced the best 
performance. Our computational model supports this interplay between receptor density and 
dual-targeted ligand ratios. Combined, these results indicate a balance required in LR kinetics, 
favoring particle designs with more ligands to the LAM receptor with the lower expression level. 
 Under flow conditions, many forces interact to prescribe the adhesion tendencies of 
VTCs. First, particles must marginate from bulk blood flow in order to interact with the 
vasculature of interest; only then does the targeting efficiency matter. Use of whole blood in our 
PPFC assay reproduces the conditions particles must overcome in vivo; particles must marginate 
to the surface, overcome collisions with blood cells, and be able to adhere in the presence of 
plasma proteins. Previous literature has demonstrated that 2-3 µm spherical particles are most 
efficient at marginating from bulk human blood flow and concentrate in the cell free layer (CFL) 
near the wall, while 100 - 500 nm particles remain uniformly distributed.
32,33
 However, smaller 
nano-sized VTCs remain appealing for the ability to safely traverse capillaries and travel through 
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intracellular and interstitial spaces in both mouse and human circulation. As the particles used in 
this study were all of the same size and material, margination dynamics, and thus interaction 
potential with the vascular wall, can be considered uniform across all trials; all effects observed 
are attributable to variations in the surface ligands. 
 In both our in vitro and in vivo results, increasing sLe
A
 densities produced increased 
adhesion. This increase in single ligand density also slowed the rolling velocity of particles, 
which has previously been demonstrated for sLe
A
 functionalized particles over a coated 
surface.
36
 As more LR pair interactions occur, the aggregate LR interaction forces overcome the 
wall shear force to establish firm adhesion. Avidin’s multivalency increases the likelihood of 
clustered targeting ligands, yet our surface densities never saturated the available avidin sites 
(Figure S2). General increases in ligand density increases the likelihood of a viable spatial 
orientation that favors LR interactions. However, there were diminishing returns to adding more 
sLe
A
 on the particle surface in vivo. Other researchers have discussed the steric hindrance limit 
of antibody ligands, such that too many antibodies on a particle surface block each other from 




 is a small carbohydrate 
unlikely to cause steric hindrance, our results indicate a similar trend, showing a clear limit of 
diminishing returns of particle adhesion with increasing site density. Adding more sites of sLe
A 
did not significantly hinder particle adhesion over the range of densities tested, these data 
disprove the mantra that “the more, the better” for particle ligands.  
The dual-ligand VTC particles studied here target both the selectin and β2 integrin 
mediated paths of adhesion to inflamed endothelium. Most previous work in dual ligand particles 
explores targeting inflammatory surface molecules with mixes of antibodies.
18,21,22,39
 Our work 
aims to explore a dynamic mixing of a carbohydrate-selectin LR pair with an antibody-CAM LR 
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pair, which have drastically different kinetics.
34,35
 We first explored the benefit of having two 
ligands on a single particle, to determine if particle adhesion from a dual-targeted particle is 
merely the sum from the two different ligands. To answer this, we evaluated the series of 





 resulted in non-significant increases in either firmly 
arrested (A-B, E-G) or rolling (A-B, E-G) particles. When we compare these individual ligand 
types to dual-targeted particles F and H, we can conclude that there is a more than additive effect 
when blending the two ligand types. For example, the total number of adhesive particles for 
dual-targeted particle F is more than the addition of particle A and E; this is also true when 
comparing particle H to the sum of adhesion from B and G. Particles F and H resulted in 
increased rolling and adhesive densities compared to both of the single-ligand particle types. As 
explained with the rolling velocities, this is likely due to the synergistic activity of the two 
ligands; sLe
A
 facilitates initial adhesion, but the rapid off rate guarantees some level of particle 
rolling,
34
 while aICAM facilitates firm adhesion after an initial interaction.
35
 When both ligands 
are present, the behaviors blend to allow initial rolling and eventual firm capture, similar to 
leukocytes. Various investigations into leukocyte adhesion in vivo have demonstrated the 
importance of endothelial expression of both selectins and CAMs on cell rolling and adhesion.
40–
43
 Providing a variety in the ligand presentation on particles corresponding to physiological ratios 
of endothelial receptors provides additive benefits for VTCs targeting a dynamic endothelium.  
As Figures 1, 2, and 6B demonstrate, increasing the total site density can increase particle 
adhesion both in vitro, in vivo, and in silico. To eliminate the suspicion that comparative 
observations in Figure 3 are purely due to the increased total site density, we compared particles 
of the same total ligand density (10,000 sites/µm
2
), as shown in Figures 4-6. Our results show 
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that an optimal particle ligand ratio exists based on the surface expression of the endothelium, 
where the most effective particle type has a blend of both ligands and a ratio favoring the least 
expressed receptor. These results were initially counter-intuitive. At maximum expression of E-
selectin (4 hr, Figure 5C), we hypothesized that the sLe
A
/E-selectin interaction would control 
particle adhesion, with greater amounts of sLe
A
 resulting in greater adhesion to the dominant 
receptor. Instead, our results show the most adhesion for particle J, with 25% sLe
A
:75% aICAM. 
A parallel trend was observed at maximum expression of ICAM (24 hr, Figure 5D), where the 
most adhesion was achieved with particle I, with 75% sLe
A
:25% aICAM. Furthermore, the in 
vivo results shown in Figure 4C match this adhesion trend in Figure 5D. The receptor profile was 
not explicitly quantified in the mesentery, but it is known that rapid inflammation induced by 
topical TNF-α results in P-selectin expression within minutes of stimulation, in addition to 




 binds non-specifically to all selectins, facilitating 
the adhesive sLe
A
-selectin LR pair interaction. Though uncharacterized, the total number of 
ICAM receptors is likely higher than P-selectin within our short, 3 min activation.
46
 Combined, 
these in vitro and in vivo data support the conclusion that the best ligand design of a particle is 
dependent on the surface expression of the ECs, showing better adhesion with more ligand for 
the lesser-expressed receptor. 
These results are further explained by the in silico model. While simplistic in particle 
dynamics in blood flow, this model crucially incorporates true kinetics of each LR pair, as well 
as the shear force dynamics of particles at the wall. The model provides a method to compare 
particle adhesion for a range of particle ligand combinations, incorporating LR-pair kinetics. The 
heat maps in Figure 6D demonstrate how particle binding patterns shift with both selectin and 
ICAM receptor densities, across 5 particle types with a constant total number of sites. These 
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diverse profiles indicate that each surface receptor presentation corresponds with an optimal 
particle-ligand ratio, as driven by the kinetics of the LR pairs involved. There is a clear balance 
between ligand types based on differences in their on/off rate at the molecular level, which drives 
ka and kd at the transport continuum level. Furthermore, these heat maps corroborate the in vitro 
and in vivo trends of dual-targeted particle adhesion. At the highest levels of selectin receptor 
and basal levels of ICAM in silico, particle I exhibits the highest binding of the five particles 
tested. The in silico model also identifies ranges of receptors which would corroborate the 
parallel trend at maximum ICAM. Such consideration of the LR pair kinetics and flow 
conditions explains our in vitro and in vivo findings of ligand preference to reach the less 
dominant receptor. Fewer ligands to the more abundant receptor are required to maximize the 
benefit of that LR pair (rolling or firm adhesion, for sLe
A
 and ICAM, respectively). Additionally, 
more ligands lesser-expressed receptor increases the likelihood that the ligands find the LR pair 
for an adhesive interaction. Our in silico analysis provides clear validation that particle binding 
depends strongly on the LR kinetics and a balance of particle ligand and target receptor densities. 
This model could be readily applied to other combinations of LR pairs to predict particle 
adhesion; the corresponding receptor densities of a given surface would allow comparison 
between particle designs in order to determine the particle with the highest binding potential. 
Few studies have delved deeply into the direct effect of each LR pair on multi-targeted 
particles.
30,35,39
 Of those, there has been in vitro research corroborating that particle adhesion and 
rolling velocities depend on both the receptor density, as represented by coated plate coverage, 
and the particle ligand density.
35,47
 In these coated plate studies, particles with increasing 
amounts of aICAM provided improved firm binding regardless of dominant plate receptor 
composition.
28
 Particles functionalized in these studies had ligand site densities typically less 
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 Our in vitro findings further differ in three key ways, utilizing TNF-α 
activated ECs rather than receptor coated plates, 500 nm particles instead of 6 µm, and whole 
blood in place of buffer flow, all of which more closely capture the physiological dynamics at 
the surface of the vascular wall. Our in vitro findings are also supported by recent work with 2 
µm particles coated with variable ratios of the antibody ligands aICAM and anti-E-selectin, 
where optimal binding was achieved by a particle of 70:30 aICAM:anti-E-selectin ligand 
composition following 4 hr HUVEC activation.
39
 Unfortunately, the total ligand site density was 
not evaluated in this study. Here, we attribute the success of this particle combination to the 
surface receptor expression, rather than the cited geometry of the flow channel. This work on 
larger, 2 µm particles suggests that the same optimal presentation of ligands on the particle can 
be extended to particles of different sizes.  
Optimization of VTC particle designs that utilize dual targeting is expected to provide 
improved delivery to the vascular wall. As demonstrated via intravital microscopy, the dual-
targeted VTCs studied here rapidly and efficiently adhere to the inflamed endothelium. 
Importantly, these combinations of ligands provided minimal off target adhesion, resulting in 
high targeting specificity. Our work suggests that cargo-loaded VTCs with these ligand 
decorations can provide highly efficient binding to the vascular endothelium, especially when 
optimized towards the known receptor profiles of the target disease. In addition to this 
application towards drug delivery, there are possible diagnostic applications of this work. 
Particle adhesion with dual-targeted particles could help determine the surface expression of 
diseased endothelium, providing a diagnostic tool to determine stage of a disease with a simple 
IV injection of a blend of dual-targeted particles. 
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MATERIALS AND METHODS 
Study Approvals 
Human blood used in all assays was obtained via venipuncture according to a protocol 
approved by the University of Michigan Internal Review Board. Informed, written consent was 
obtained from all subjects prior to blood collection. Umbilical cords were obtained under a 
University of Michigan Medical School Internal Review Board (IRB-MED) approved human 
tissue transfer protocol, which is exempt from informed consent per federal exemption category 
#4 of the 45 CFR 46.101.(b). 
 Animal studies were conducted in accordance with National Institutes of Health 
guidelines for the care and use of laboratory animals and approved by the Institutional Animal 
Care and Use Committee (IACUC) of University of Michigan. C57BL/6 mice were obtained 
from Jackson Laboratories. All animals were maintained in pathogen-free facilities at the 
University of Michigan and used between 3-6 weeks in age. 
 
Cell Culture 
Human umbilical vein endothelial cells (HUVECs) used in all assays were isolated from 
healthy umbilical cords (Mott Children’s Hospital, Ann Arbor, MI) via a collagenase perfusion 
method.
48
 Isolated HUVEC were cultured in T75 flasks and seeded onto glass coverslips coated 
with gelatin (cross linked with glutaraldehyde) at 37°C and 5% CO2 with standard media until 




Flow Cytometry of HUVEC 
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 6 well plates were coated with gelatin (cross linked with glutaraldehyde) and seeded with 
HUVEC at a confluent density. The cells were activated with TNF-α (Fitzgerald, 10 ng/ml in 
complete cell media) for varying time points. Following activation, the cells were trypsinized, 
divided into multiple samples, and stained with antibodies of CD54, CD62E, and an isotype 
control IgG1 (R&D Systems) at 4°C. All subsequent steps were performed at 4°C. After 20 mins 
of staining, samples were washed twice in PBS with 0.5% BSA. Flow cytometry data was 
collected on an Attune NxT Focusing flow cytometer (Life Technologies) and analyzed using 
FlowJo software (Tree Star). Data for activated cells are presented as compared to unactivated 
cells. All data have the appropriate isotype controls subtracted from the MFI.  
 
Particle functionalization 
Carboxylated, polystyrene (Fluoresbrite® YG Polysciences, Inc) particles of 500 nm 
diameter, were covalently modified with NeutrAvidin® Biotin-Binding Protein (Thermo 
Scientific) via carbodiimide chemistry. Particles were washed with MES buffer and incubated 
with a NeutrAvidin® solution (5 mg/ml) for 15 mins at room temperature, after which an equal 
volume of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 75 mg/ml) 
was added and pH adjusted to 9.0. After incubating for 24 hrs, glycine (7.5 mg/ml) was added 
for 30 mins to quench the reaction. NeutrAvidin®-conjugated particles were then washed with a 
PBS buffer (50 mM) and stored at 4°C until ligand conjugation.  
For ligand conjugation, NeutrAvidin®-conjugated particles were incubated for 45 mins 




, Glycotech) and biotinylated 
antibodies (anti-mouse ICAM-1, rat-IgG2b, Biolegend, or anti-human ICAM-1, R&D Systems) 
at room temperature. Following incubation, particles were washed with PBS buffer containing 
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calcium and magnesium ions and 1% BSA and were then stored at 4°C until same day use for 
flow adhesion experiments, intravital microscopy, or ligand site characterization. Anti-
cutaneous-lymphocyte-associated antigen-APC (Myltenyi Biotec) and anti-rat-IgG2b-PE 
(eBioscience) were used to calculate the corresponding ligand surface densities via flow 




Parallel plate flow chamber adhesion assay 
 Venous blood was collected from healthy adults into a syringe using acid-sodium citrate-
dextrose (ACD) as anticoagulant and stored at 37°C until use; all assays utilized freshly drawn 
blood. ACD chelates calcium and inhibits particle internalization for the assay duration.
51
 
Confluent HUVEC monolayers were activated with TNF-α (Fitzgerald, 10 ng/ml in complete 
cell media) for 4 or 24 hrs under static conditions at 37°C and 5% CO2 to induce E-selectin and 
ICAM-1 expression. Blood containing ligand-coated particles at 5x10
6
 particles/mL was 
perfused over the activated HUVEC monolayer attached to a PPFC (Glycotech) in a laminar 
flow profile. The wall shear rate (WSR, γw) was fixed to 200 s
-1
 by adjustment of the volumetric 








where h is the channel height (0.0127 cm), w the channel width (0.25 cm), and Q the volumetric 
flow rate (mL/sec). Q was calculated as 82 µL/min in this system. The h of 127 µm and γw of 
200 s
-1
 were chosen to mimic the flow profile within a vein/venule of similar dimensions to those 
studied via intravital microscopy.
52,53
 After blood perfusion of 5 min, PBS buffer containing 1% 
BSA was added to PPFC and particle adhesion densities were assessed via optical imaging using 
a Nikon TE-2000-S inverted microscope with a digital camera (Photometrics CoolSNAP EZ 
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with a Sony CCD sensor). Due to the addition of buffer flow, only adherent particles are 
quantified in this assay. Results were imaged and analyzed via NIS-Elements® analysis software 
and ImageJ.  
 
Intravital fluorescence microscopy 
 Visualization of mesentery vessels was performed as previously described.
54,55
 Briefly, 
female mice (3-4 weeks old) were anesthetized and a tail vein catheter placed for delivery of 
particles. Mice were placed on a custom-made microscope heated stage at 37°C, and the 
mesentery was exteriorized to a glass cover slip via midline incision. Imaged vessels were 
chosen based on size, with the diameter of veins ranging from 100 - 200 µm, with an average of 
153 µm. Following vessel selection, local injury was induced by topical application of TNF-α 
(Fitzgerald, 10 µL of 200 µg/mL in PBS). Particles suspended in PBS were injected 3 mins 
following topical TNF-α application via IV catheter and imaged for another 5 mins. Mice 
received 3x10
9
 particles in 200 µL injection volume, corresponding to ~0.2 mg/mouse, 
~10mg/kg. Targeted particle rolling and adhesion in mesenteric veins were visualized using a 
25x oil objective an inverted fluorescence microscope (Zeiss Axio Observer Z1 Marianas 
Microscope) Images were recorded continuously in green fluorescence every 10 ms using 
Slidebook 6 software.  
 Analysis was performed using Slidebook 6 and ImageJ using blinded file names. Particle 
rolling velocities were obtained using particle tracking software, and all paths were manually 
confirmed until at least 50 particles were tracked per experimental condition. Vessels were 
isolated and measured using Slidebook 6. Particles found in adjacent vessels but within the frame 
were excluded from the analysis. Particles were considered adherent when they appeared in the 
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same location for ten consecutive frames of the particle tracking. Particles were considered 
rolling when their tracked paths moved less than 50 µm between frames. Firmly adhered 
particles did not contribute to the rolling velocity data. 
  
Particle Adhesion Simulation  
Particle adhesion was simulated in a 2D rectangular channel using COMSOL 5.2 through 
a combined continuum and particulate model, adapted from previous work and described in 
detail in the Supplemental Material.
30,56
 Briefly, a velocity profile was established for an 
incompressible Newtonian fluid in a rectangular channel with dimensions 10 x 30 µm, with a 
reactive surface of 10 µm along the bottom wall. Unless otherwise designated, a wall shear rate 
of 200 s
-1
 was imposed (average channel velocity 1.67 mm/s). A continuum model was 
developed to evaluate particle transport, considering both convection and diffusion and solved 





where C is the particle concentration and D is the particle mass diffusivity. The ligand-receptor 




=  −  
(3) 
where B is the number of bound particles on the reactive surface and Cw is the particle 
concentration near the wall. The variables ka and kd are the attachment and detachment rates of 
the ligand functionalized nanoparticles, respectively; both are functions of the forward (kf) and 
reverse (kr) ligand-receptor bonding rates, the total number of ligands (NL) and receptors (NR), 
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and the physical properties of the particles and fluid medium. These were approximated using a 
particulate model to capture the molecular level ligand-receptor interactions, by establishing a 
total bond density, Nb, between surfaces, with each ligand-receptor interaction treated as 
independent values (Nb-1 for ICAM-aICAM interactions, Nb-2 for selectin-sLe
A
 interactions): 
 =  + =	 +
1








where c7, c8, c17, c14, c15, and c16 are constants containing kf, kr, NL-sLe
A
, NL-aICAM, NR-
selectin, and NR-ICAM as derived in the Supplemental Material. The forward (kf) and reverse 
(kr) ligand-receptor bonding rates have been determined for aICAM/ICAM and sLe
A
/selectin in 
the literature, as reported in the supplement.
34,35
 Following analysis by Tan et al. and use of a 
force balance, representative times of Tr, Td and Tdebond were determined using the expression of 









where d is a representative length, chosen to be the diameter of the particle.
56
  
Using the derived reaction boundary condition, B was determined as a function of time, 
NL-aICAM, NL-sLe
A
, NR-ICAM, NL-selectin, shear rate, and position on the reactive surface for 
a constant uniform inlet concentration of particles at 5x10
9 
/ml. To obtain the total concentration 
bound, B was integrated over the 10 µm reactive boundary. As this model does not incorporate 
the variable regio-specific presentation of receptors at the endothelium wall, or differences 
between the interaction strengths of sLe
A
/selectin and aICAM/ICAM, the range of ligand and 
receptor densities of the four parameters were evaluated under conditions where each of these 
four parameters contributed to particle binding, as listed in the Supplemental Material. 
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 Characterization of HUVEC expression after TNF-α activation is representative of two 
independent experiments from different cell isolations, with two technical replicates each. PPFC 
flow experiment data is an average of 10 pictures from each individual experiment, with n≥3 
blood donors for each group of data presented. Intravital results represent averages from at least 
3 different imaging sequences of different vessels within groups, n≥3 mice per group. For all 
studies, all data points were included in the analyses and no outliers were excluded in 
calculations of means or statistical significance. Data are plotted with standard error bars and 
analyzed as indicated in figure legends. Asterisks indicate p values of *<0.05, **<0.01, 
***<0.001 and n.s indicates not significant. 
 
CONCLUSIONS 
Overall, the work presented here represents a truly novel demonstration of particle 
binding to an inflamed mesentery via intravital microscopy. We have shown that the adhesive 
abilities of 500 nm particles, which are not preferentially excluded to the vascular wall from 
blood flow, can be significantly improved by targeting ligand design. While the total number of 
sites of a single ligand can drive particle adhesion to the endothelium, combining LR pairs from 
multiple LAM interactions provides a more powerful approach. These dual-targeted ligand 
designs should be optimized based on the surface endothelium, with ligand coating densities 
favoring the less-predominant adhesive receptor, as driven by the LR pair kinetics. The 
knowledge presented here about the importance of the LR pair matching will help in the 
intelligent particle ligand design for future applications in all diseases benefitting from VTCs, 
including atherosclerosis, cancer, inflammation, and many more.  
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A 5,000 0 5,000 
 5.642 +/- 929 0 5.642 
B 10,000 0 10,000 
 10,374 +/- 1,369 0 10,374 
C 20,000 0 20,000 
 19,623 +/- 1.920 0 19,623 
D 40,000 0 40,000 
 41,040 +/- 2,225 0 41,040 
E 0 5,000 5,000 
 0 4,526 +/- 1,892 4,526 
F 5,000 5,000 10,000 
 3,866 +/- 487 4,717 +/- 1,006 8,583 
G 0 10,000 10,000 
 0 10,938 +/- 2,536 10,938 
H 10,000 10,000 20,000 
 11,495 +/- 4,631 10,987 +/- 2,466 22,482 
I 7,500 2,500 10,000 
 6,792 +/- 911 2,976 +/- 675 9,768 
J 2,500 7,500 10,000 
 2,910 +/- 127 8,891 +/- 220 11,801 
 
 *Particle types A-J and corresponding ligand densities. Target values shown in grey, with actual 
values determined via flow cytometry shown below, n ≥ 2 particle batches, standard deviation 




Figure 1. Particle adhesion to inflamed HUVEC monolayer as a function of total sLe
A
 sites. 
(A) Diagram of four particle conditions A-D with increasing sLe
A
 ligand density (5,000, 10,000, 
20,000, and 40,000 sLe
A
 sites). (B) Representative fluorescence images of particle adhesion to in 
vitro inflamed HUVEC monolayer, corresponding to particles A-D from top to bottom. HUVEC 
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activation was achieved via 4 hr TNF-α incubation. (C) Quantified particle adhesion. Statistical 
analysis was performed using one-way ANOVA with Fisher’s Least Significant Difference 
(LSD) test (*) indicates p<0.05, n=3 donors. Error bars represent standard error, scale bar 50 µm. 
 
Figure 2. Particle adhesion to inflamed mesentery endothelium as a function of total sLe
A
 
sites. (A) Representative fluorescence images of particle adhesion to inflamed mesentery, top 
images correspond to particles A and B (left to right, 5,000 and 10,000 sLe
A
 sites), bottom 
images correspond to particles C and D (left to right, 20,000 and 40,000 sLe
A
 sites). Particle 
fluorescence shown in green, overlaid on the bright field image. (B) Quantified adherent density 
of firmly bound and rolling particles per representative imaging segment, n = 3 mice. Statistical 
analysis was performed using one-way ANOVA with Fisher’s LSD test between total adherent 
particles: (*) indicates p<0.05, and two-way ANOVA with Fishers LSD test between groups: ($) 
indicates p<0.05 between rolling groups, firm non-significant (n.s.). (C) Velocity of rolling 
particles found at mesentery wall, n ≥ 50 particles from n = 3 mice. Statistical analysis was 
performed using one-way ANOVA with Fisher’s LSD test, with all interactions p<0.001 except 
where indicated. Error bars represent standard error, scale bar 50 µm. 
 
Figure 3. Particle adhesion to inflamed mesentery endothelium as a function of combined 
sLe
A
 and aICAM sites. Comparison of dual-targeted particle designs with single ligand 
densities of (A) 5,000 sites/µm
2
 and (B) 10,000 sites/µm
2
. Left: Diagram of particle conditions 
with varied amounts of sLe
A
 and aICAM ligand density. Middle: Quantified adherent density of 
firmly bound and rolling particles per representative imaging segment, n = 3 mice. Left: Velocity 
of rolling particles found at mesentery wall, n ≥ 50 particles from n = 3 mice. Statistical analysis 
of adherent density was performed using one-way ANOVA with Fisher’s LSD test between total 
adherent particles (*) indicates p<0.05, (**) p<0.01 and two-way ANOVA with Fishers LSD test 
between groups, (#) indicates p<0.05, (##) p<0.01 between firm groups, rolling groups n.s. 
Statistical analysis of rolling velocity was performed using one-way ANOVA with Fisher’s LSD 
test, (***) indicates p<0.001. Error bars represent standard error. 
 
Figure 4. Particle adhesion to inflamed mesentery endothelium as a function of varied 
ratios of sLe
A
 and aICAM sites. (A) Diagram of five particle conditions with varied amounts of 
sLe
A
 and aICAM ligand density at a constant total site density of 10,000 sites/µm
2
. (B) 







ICAM) adhesion to inflamed mesentery, scale bar 50 µm. (C) Quantified number of fixed or 
rolling particles on inflamed mesentery per representative imaging segment, n=3 mice. Statistical 
analysis of adherent density was performed using one-way ANOVA with Fisher’s LSD test 
between total adherent particles: (*) indicates p<0.05 and two-way ANOVA with Fishers LSD 
test between groups (##) p<0.01 between firm groups, rolling groups n.s. (D) Velocity of rolling 
particles found at mesentery wall, n ≥ 50 particles from n = 3 mice. Statistical analysis of rolling 
velocity was performed using one-way ANOVA with Fisher’s LSD test, (*) indicates p<0.05, 
n.d. indicates none detected and excluded from the analysis. Error bars represent standard error. 
 
Figure 5. Particle adhesion to HUVEC monolayer as a function HUVEC surface 
expression. (A) Representative fluorescence images of HUVEC surface expression of E-selectin 
and ICAM at 4 hr and 24 hr post TNF-α activation, scale bar 10 µm. (B) HUVEC surface 
expression of E-selectin and ICAM (left to right) over time determined via flow cytometry, 
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representative gating in Supplemental Figure 5. Shown as fold increases of MFI over unactivated 
cells. Quantified particle adhesion following 5 min PPFC assay after (C) 4 hr and (D) 24 hr TNF-
α activation for particles at constant total site density but varied ligand ratios. Statistical analysis 
was performed using one-way ANOVA with Fisher’s LSD test (*) indicates p<0.05, (***) 
indicates p<0.001 between all groups, n=3 donors. Error bars represent standard error. 
 
Figure 6. Computational model of particle adhesion as a function of ligand and receptor 
density. (A) Simulation geometry and flow profile (top), with representative resultant particle 
concentration profile within the fluid (bottom) in #/µm
2
. Bound particles not represented in the 
visualization. The bound particle concentration (B) over time at constant shear 200 s
-1
 with (B) 
constant receptor (NR) density, and (C) constant ligand (NL) density. (D) Heat maps of B at 1 sec 
and constant shear 200 s
-1
 as a function of NR-ICAM and NR-selectin
 
for five particle combinations 
with varied NL
 
ratios. Blue indicates NR conditions of more adherent particles and red indicating 













, both equally spaced. 
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Figure 1. Particle adhesion to inflamed HUVEC monolayer as a function of total sLeA sites. (A) Diagram of 
four particle conditions A-D with increasing sLeA ligand density (5,000, 10,000, 20,000, and 40,000 sLeA 
sites). (B) Representative fluorescence images of particle adhesion to in vitro inflamed HUVEC monolayer, 
corresponding to particles A-D from top to bottom. HUVEC activation was achieved via 4 hr TNF-α 
incubation. (C) Quantified particle adhesion. Statistical analysis was performed using one-way ANOVA with 
Fisher’s Least Significant Difference (LSD) test (*) indicates p<0.05, n=3 donors. Error bars represent 
standard error, scale bar 50 µm.  
114x106mm (150 x 150 DPI)  
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Figure 2. Particle adhesion to inflamed mesentery endothelium as a function of total sLeA sites. (A) 
Representative fluorescence images of particle adhesion to inflamed mesentery, top images correspond to 
particles A and B (left to right, 5,000 and 10,000 sLeA sites), bottom images correspond to particles C and D 
(left to right, 20,000 and 40,000 sLeA sites). Particle fluorescence shown in green, overlaid on the bright 
field image. (B) Quantified adherent density of firmly bound and rolling particles per representative imaging 
segment, n = 3 mice. Statistical analysis was performed using one-way ANOVA with Fisher’s LSD test 
between total adherent particles: (*) indicates p<0.05, and two-way ANOVA with Fisher's LSD test between 
groups: ($) indicates p<0.05 between rolling groups, firm non-significant (n.s.). (C) Velocity of rolling 
particles found at mesentery wall, n ≥ 50 particles from n = 3 mice. Statistical analysis was performed using 
one-way ANOVA with Fisher’s LSD test, with all interactions p<0.001 except where indicated. Error bars 
represent standard error, scale bar 50 µm.  
173x113mm (150 x 150 DPI)  
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Figure 3. Particle adhesion to inflamed mesentery endothelium as a function of combined sLeA and aICAM 
sites. Comparison of dual-targeted particle designs with single ligand densities of (A) 5,000 sites/µm2 and 
(B) 10,000 sites/µm2. Left: Diagram of particle conditions with varied amounts of sLeA and aICAM ligand 
density. Middle: Quantified adherent density of firmly bound and rolling particles per representative imaging 
segment, n = 3 mice. Left: Velocity of rolling particles found at mesentery wall, n ≥ 50 particles from n = 3 
mice. Statistical analysis of adherent density was performed using one-way ANOVA with Fisher’s LSD test 
between total adherent particles (*) indicates p<0.05, (**) p<0.01 and two-way ANOVA with Fisher's LSD 
test between groups, (#) indicates p<0.05, (##) p<0.01 between firm groups, rolling groups n.s. Statistical 
analysis of rolling velocity was performed using one-way ANOVA with Fisher’s LSD test, (***) indicates 
p<0.001. Error bars represent standard error.  
176x110mm (150 x 150 DPI)  
 
 
Page 38 of 40Bioengineering & Translational Medicine













Figure 4. Particle adhesion to inflamed mesentery endothelium as a function of varied ratios of sLeA and 
aICAM sites. (A) Diagram of five particle conditions with varied amounts of sLeA and aICAM ligand density at 
a constant total site density of 10,000 sites/µm2. (B) Representative fluorescence image of particle I (7,500 
sites/µm2 sLeA: 2,500 sites/µm2 anti-ICAM) adhesion to inflamed mesentery, scale bar 50 µm. (C) 
Quantified number of fixed or rolling particles on inflamed mesentery per representative imaging segment, 
n=3 mice. Statistical analysis of adherent density was performed using one-way ANOVA with Fisher’s LSD 
test between total adherent particles: (*) indicates p<0.05 and two-way ANOVA with Fishers LSD test 
between groups (##) p<0.01 between firm groups, rolling groups n.s. (D) Velocity of rolling particles found 
at mesentery wall, n ≥ 50 particles from n = 3 mice. Statistical analysis of rolling velocity was performed 
using one-way ANOVA with Fisher’s LSD test, (*) indicates p<0.05, n.d. indicates none detected and 
excluded from the analysis. Error bars represent standard error.  
141x110mm (150 x 150 DPI)  
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Figure 5. Particle adhesion to HUVEC monolayer as a function HUVEC surface expression. (A) Representative 
fluorescence images of HUVEC surface expression of E-selectin and ICAM at 4 hr and 24 hr post TNF-α 
activation, scale bar 10 µm. (B) HUVEC surface expression of E-selectin and ICAM (left to right) over time 
determined via flow cytometry, representative gating in Supplemental Figure 5. Shown as fold increases of 
MFI over unactivated cells. Quantified particle adhesion following 5 min PPFC assay after (C) 4 hr and (D) 24 
hr TNF-α activation for particles at constant total site density but varied ligand ratios. Statistical analysis 
was performed using one-way ANOVA with Fisher’s LSD test (*) indicates p<0.05, (***) indicates p<0.001 
between all groups, n=3 donors. Error bars represent standard error.  
180x133mm (150 x 150 DPI)  
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Figure 6. Computational model of particle adhesion as a function of ligand and receptor density. (A) 
Simulation geometry and flow profile (top), with representative resultant particle concentration profile within 
the fluid (bottom) in #/µm2. Bound particles not represented in the visualization. The bound particle 
concentration (B) over time at constant shear 200 s-1 with (B) constant receptor (NR) density, and (C) 
constant ligand (NL) density. (D) Heat maps of B at 1 sec and constant shear 200 s-1 as a function of NR-
ICAM and NR-selectin for five particle combinations with varied NL ratios. Blue indicates NR conditions of 
more adherent particles and red indicating conditions of fewer adherent particles. NR-ICAM ranges from to 
1x10-6 to 3x10-4 µm-2, while NR-selectin ranges from to 1x10-6 to 3.5x10-5 µm-2, both equally spaced.  
191x111mm (150 x 150 DPI)  
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